Related content

Comparison of HapMap data on Affymetrix and Illumina platforms: expanding the power of studies and a not so unexpected synergy

By Dobrin Seth  

Pharmacogenomics, Vol. 8, Iss. 2, 2007-02 ,pp. : 199-201

Future Medicine

Access to resources Recommend Favorite

RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients

By Cao Xueyuan   Mitra Amit K   Pounds Stanley   Crews Kristine R   Gandhi Varsha   Plunkett William   Dolan M Eileen   Hartford Christine   Raimondi Susana   Campana Dario   Downing James   Rubnitz Jeffrey E   Ribeiro Raul C   Lamba Jatinder K  

Pharmacogenomics, Vol. 14, Iss. 12, 2013-09 ,pp. : 1449-1466

Future Medicine

Access to resources Recommend Favorite

Alexza Pharmaceuticals has announced that it has completed enrolment in its second phase III trial with loxapine

By  

Inpharma, Vol. 1, Iss. 1661, 2008-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Enrolment for the second Statin Response Examined by Genetic Hap™ Markers trial

By  

Inpharma, Vol. 1, Iss. 1322, 2002-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Enrolment has been completed in a phase III study evaluating salmon calcitonin for vertebral fractures in postmenopausal women.

By  

Inpharma, Vol. 1, Iss. 1651, 2008-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite